Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Total Current Liabilities

All obligations due within one year.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Total Current Liabilities · Q4 FY2025 · quarter ended Dec 2025

Total current liabilities falls 94.9% from a year ago

Total current liabilities stood at $87.84K at the end of Q4 FY2025, down 94.9% from a year earlier. Over 3 fiscal years it compounded at -60.4% a year.

Context

  • Total current liabilities amounted to 0.3% of total assets at the end of Q4 FY2025, down 8.9 pp from a year earlier.
  • Total current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -94.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$87.84K— QoQ
Last fiscal yearDec 2025
$87.84K-94.9% YoY
Year agoDec 2024
$1.73M-94.9% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-94.9%——
1 year-94.9%——
3-year CAGR-60.4%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
87.84K USD
Year-over-year change
-94.9%
4-year CAGR
-56.2%

Total Current Liabilities vs competitors

How NNNN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -94.9% is the lowest of 10, against a peer median of +17.2%.
  • Total current liabilities amounts to 0.3% of total assets for NNNN, versus a peer median of 17.4%.
NNNN Competitors
Total Current Liabilities for NNNN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CYHCommunity Health Systems, Inc.Mar 2026$2.57B USD+8.3%+0.3%19.5%
CMPSCOMPASS Pathways plcMar 2026$153.8M USD+412.7%+151.4%28.9%
AVNSAvanos Medical, Inc.Mar 2026$131.2M USD-4.4%-4.7%12.5%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$89.49M USD+34.3%+15.0%17.7%
SNDLSNDL Inc.Mar 2026CA$86.73M CAD-4.9%+1.1%6.6%
ANGOAngioDynamics, Inc.Feb 2026$66.07M USD-15.3%+0.8%25.3%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$57.36M USD——17.1%
GOSSGossamer Bio, Inc.Mar 2026$56.51M USD+17.2%+8.8%43.8%
TALKTalkspace, Inc.Mar 2026$22.81M USD+19.3%-14.0%16.7%
CLPTClearPoint Neuro, Inc.Mar 2026$9.48M USD+38.1%+16.6%10.1%
NNNNAnbio Biotechnology Class A Ordinary SharesDec 2025$87.84K USD-94.9%-60.4%0.3%
Peer median (excluding NNNN) —+17.2%+1.1%17.4%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.18M7.1M9.69M11.76M7.77M
Short-term Investments01.57M004.13M
Net Receivables717.5K3.58K1.88M1.06M3.66M
Inventory0353.87K000
Other Current Assets00000
Total Current Assets4.92M13.94M15.75M18.53M30.24M
Property, Plant & Equipment (Net)012.06K000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets02.99K62.14K387.44K0
Total Non-current Assets015.05K62.14K387.44K0
Total Assets4.92M13.96M15.81M18.92M30.24M
Account Payables1.89M1.41M827.15K1.63M0
Short-term Debt00000
Tax Payables00000
Deferred Revenue490K0000
Other Current Liabilities00000
Total Current Liabilities2.38M1.41M993.06K1.73M87.84K
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities00000
Total Liabilities2.38M1.41M993.06K1.73M87.84K
Common Stock0014.23K14.23K14.39K
Retained Earnings2.54M12.55M14.8M17.17M23.58M
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity2.54M12.55M14.82M17.19M30.16M
Total Debt00000
Net Debt(4.18M)(7.1M)(9.69M)(11.76M)(7.77M)

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.